<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1605">
  <stage>Registered</stage>
  <submitdate>28/06/2007</submitdate>
  <approvaldate>28/06/2007</approvaldate>
  <nctid>NCT00494117</nctid>
  <trial_identification>
    <studytitle>Investigation of Heart Failure Status Over Time Using Respiratory Parameters</studytitle>
    <scientifictitle>Investigation of Heart Failure Status Over Time Using Respiratory Parameters</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>X07- 0052</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Heart Failure, Congestive</healthcondition>
    <healthcondition>Sleep Apnea Syndromes</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Sleep apnoea</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - ApneaLink

Treatment: devices: ApneaLink
A two channel sleep screening device for the assessment of Sleep Disordered Breathing.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>-  Moderate to severe Heart Failure (as determined by Echocardiogram or by treating
             physician)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Malignant disease affecting gas exchange or respiratory parameters

          -  Medications compromising breathing with no adverse affects on heart failure

          -  Clinically significant (moderate to severe) asthma requiring therapy

          -  Chronic parenchymal lung disease (FEV1/FVC ratio = 65% or as determined by the
             treating physician)

          -  Severe pulmonary hypertension

          -  Heart failure due to alcohol abuse or chemotherapy

          -  Narcotic abuse/intravenous drug use (including HIV+ and hepatitis C)

          -  Alcohol consumption &gt; 80g/day

          -  Patients receiving home Oxygen

          -  Methicillin- resistant Staphylococcus aureus infection

          -  Narcolepsy

          -  Cataplexy

          -  Enrolled in any concurrent study, that may confound the results of this study.

          -  Inability or refusal to sign the Patient Consent Form

          -  Inability or refusal to adhere to protocol requirements</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>50</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <postcode>2050 - Camperdown</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>ResMed</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to investigate respiratory indicators for clinically important
      changes in Heart Failure status over time.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00494117</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Rachel A Coxon, BE/MBiomedE</name>
      <address>ResMed/The University of New South Wales</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>